The focus of HEP DART 2009 is to assemble clinicians, researchers and basic scientists together to advance our knowledge of the ongoing drug development processes in the treatment of hepatitis B and hepatitis C and other viruses affecting the liver, including co-infections with HIV.
HEP DART 2009 will uniquely blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community with an increased understanding of the current and future challenges in therapeutics for hepatitis infection.
Conference Program Highlights
The conference program includes sessions covering the following topics:
- Global Burden of HBV/HCV, Natural History, and Therapeutic Management
- Pathogenesis, Therapeutics and Viral Dynamics of the Hepatitis Viruses
- Emerging Viral Issues
- Advances in HCV Basic Science
- Next Generation of HBV and HCV Inhibitors
- Therapeutic and Animal Models for HBV/HCV
- Immunological Approaches and Vaccines for Hepatitis Infections
- Optimizing Outcome of Therapeutics for Hepatitis Infections
- Liver Damage, Decompensation, Fibrosis and Hepatocellular Carcinoma
- Co-infections and Therapeutic Modalities
Continuing Medical Education
Emory University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Emory University School of Medicine designates this educational activity for a maximum of 26 AMA PRA Category 1
Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The Scientific Committee has designed the Conference program to ensure that the delegates achieve the following objectives:
- Understand the role of viral targets in the drug development and discovery process
- Identify the next generation of inhibitors of viral hepatitis
- Assess the impact of resistance and treatment failure in the drug development and discovery process
- Increase awareness of the clinical impact of antiviral agents
- Understand the consequences of co-infection with HIV on the management of patients
- Assess the role of vaccines and therapeutic vaccines in future therapies for viral hepatitis
The Conference is open to anyone interested in therapies for viral hepatitis. However, the content of this Conference was developed to interest primarily scientists and clinical researchers in the infectious diseases.